Reviva Pharmaceuticals - CW23 | 8-K: FY2025 Q2 EPS: USD -0.12

EPS: As of FY2025 Q2, the actual value is USD -0.12.

EBIT: As of FY2025 Q2, the actual value is USD -6.073 M.

Financial Results for June 30, 2025

Net Loss

• The Company reported a net loss of approximately $6.1 million, or $0.12 per share, for the three months ended June 30, 2025, compared to a net loss of approximately $7.9 million, or $0.26 per share, for the three months ended June 30, 2024.

Cash and Cash Equivalents

• As of June 30, 2025, the Company’s cash and cash equivalents totaled approximately $10.4 million compared to approximately $13.5 million as of December 31, 2024.

Operating Expenses

• Research and development expenses were $3.7 million for the three months ended June 30, 2025, compared to $5.6 million for the same period in 2024.
• General and administrative expenses were $2.3 million for the three months ended June 30, 2025, compared to $2.5 million for the same period in 2024.
• Total operating expenses were $6.1 million for the three months ended June 30, 2025, compared to $8.1 million for the same period in 2024.

Loss from Operations

• Loss from operations was $6.1 million for the three months ended June 30, 2025, compared to $8.1 million for the same period in 2024.

Other Income (Expense)

• Gain on remeasurement of warrant liabilities was $11,126 for the three months ended June 30, 2025, compared to $200,273 for the same period in 2024.
• Interest expense was $4,797 for the three months ended June 30, 2025, compared to $5,153 for the same period in 2024.
• Interest income was $22,847 for the three months ended June 30, 2025, compared to $87,610 for the same period in 2024.
• Other (expense) income, net was -$1,850 for the three months ended June 30, 2025, compared to -$5,621 for the same period in 2024.

Total Other (Expense) Income, Net

• Total other (expense) income, net was $27,326 for the three months ended June 30, 2025, compared to $277,109 for the same period in 2024.

Loss Before Provision for Income Taxes

• Loss before provision for income taxes was $6.0 million for the three months ended June 30, 2025, compared to $7.9 million for the same period in 2024.

Provision for Income Taxes

• Provision for income taxes was $7,954 for the three months ended June 30, 2025, compared to $7,385 for the same period in 2024.

Net Loss

• Net loss was $6.1 million for the three months ended June 30, 2025, compared to $7.9 million for the same period in 2024.

Outlook / Guidance

• Planned meeting with FDA to discuss brilaroxazine’s path to approval in Q4 2025.
• Potential NDA submission for brilaroxazine in schizophrenia targeted in Q2 2026.
• Investigational new drug application (IND) submission for liposomal-gel formulation of brilaroxazine in psoriasis expected by Q2-2026.